Results 171 to 180 of about 18,832,204 (305)
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Research on the influencing factors and pathways of user health information disclosure behavior on medical and health platforms: based on PLS-SEM, NCA, and fsQCA analysis. [PDF]
Yu C, Bi Y, Jia J, Liu S, Lv K.
europepmc +1 more source
Using Techniques of Geographic Information Systems (GIS) in The Municipality Services of The Kut City [PDF]
شايش, علي كريم +1 more
openalex +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
The eyes have it: a task by data type taxonomy for information visualizations
B. Shneiderman
semanticscholar +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
Study on salient object segmentation based on depth information guidance and SAM low-rank adaptation fine-tuning. [PDF]
M A W.
europepmc +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

